Media

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

Updated results from Phase 1/2 trial of Betalutin® in NHL accepted for presentation at the International Conference on Malignant Lymphoma in June

Nordic Nanovector to Present at Upcoming Deutsche Bank and Jefferies Healthcare Conferences

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

Onxeo: Q1 2017 financial information and business update

PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market

GenSight Biologics reports its cash position as of March 31, 2017